Diamyd Medical, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, reports today that the US FDA has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America...





